Skip to content
naulon

Not checkedNot checked for notices yet.

Progress and prospect of epidermal growth factor receptor tyrosine kinase inhibitor in treatment of non-small cell lung cancer

JIANG Hanshui, WU Guom

陆军军医大学学报 · 2022

doi:10.16016/j.2097-0927.202209158 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Epidermal growth factor receptor (EGFR) is the most common driver gene of mutations in advanced non-small cell lung cancer (NSCLC), and EGFR tyrosine kinase inhibitor (EGFR-TKI) has become the most important and preferred treatment. EGFR-sensitive mutations mainly consist of exon 19 deletion (19Del) mutation and exon 21 L858R mutation, accounting for about 90% of EGFR mutations, while the 19Del subtype is more sensitive and effective to EGFR-TKI. For advanced NSCLC patients with EGFR-sensitive mutations, it is standard and reasonable to select any EGFR-TKI which has been given first-line indications in our country as first-line treatment, among which osimertinib is a better choice. Osimertinib has made a breakthrough in the adjuvant treatment for early- and middle-stage NSCLC, and greatly reduced the risk of disease recurrence or death. Researches on EGFR pathway will focus on overcoming EGFR-TKI resistance, development of EGFR rare mutation inhibitors and neoadjuvant targeted therapy.

Abstract licence: CC BY

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.